January 2006 Cover
|
 |
Drug maker Biogen and the US Food and Drug Administration said Amevive, a skin drug manufactured by the biotechnology company, should not be used in patients with HIV.
On the FDA Web site, the agency and the drug maker said that Amevive, which is approved for the treatment of moderate to severe chronic plaque psoriasis, can reduce the amount of CD4+ T lymphocytes in the patient's blood, thus possibly leading to accelerated
progress of HIV or to other complications.
"Biogen, in consultation with FDA, is contraindicating Amevive in patients with HIV disease," the company said in a recent letter to health care providers.
Editor's Note: from Reuters
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
